Ignite Creation Date:
2025-12-24 @ 2:41 PM
Ignite Modification Date:
2026-01-04 @ 12:28 AM
Study NCT ID:
NCT01180959
Status:
COMPLETED
Last Update Posted:
2022-11-07
First Post:
2010-08-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-04-14
Start Date Type:
ACTUAL
Primary Completion Date:
2021-05-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-05-19
Completion Date Type:
ACTUAL
First Submit Date:
2010-08-11
First Submit QC Date:
None
Study First Post Date:
2010-08-12
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2022-04-22
Results First Submit QC Date:
None
Results First Post Date:
2022-11-07
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-11-03
Last Update Post Date:
2022-11-07
Last Update Post Date Type:
ACTUAL